Biohaven Ltd

More Details of Biohaven Ltd Company

Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.

Company Info

Ticker SymbolBHVN

Company nameBiohaven Ltd

IPO dateSep 23, 2022

Founded at2022

CEODr. Vlad Coric, M.D.

Number of employees256

Security typeOrdinary Share

Fiscal year-endSep 23

Address215 Church Street

CityNEW HAVEN

Stock exchangeNYSE Consolidated

CountryUnited States of America

Postal code06510

Phone12034040410

Websitehttps://www.biohaven.com/

Ticker SymbolBHVN

IPO dateSep 23, 2022

Founded at2022

Company Executives

Name

Name/Position

Position

Shareholding

Change

Dr. Gregory Hugh (Greg) Bailey, M.D.

Independent Director

1.62M

--

Mr. Matthew (Matt) Buten

Chief Financial Officer

193.45K

+0.39%

Dr. Bruce Car, Ph.D.

Chief Scientific Officer

34.80K

+757.19%

Ms. Julia Paige Gregory

Independent Director

25.66K

--

Mr. Michael Thomas (Mike) Heffernan

Lead Independent Director

15.18K

--

Mr. Robert J. Hugin

Independent Director

12.96K

--

Dr. Irina Antonijevic, M.D., Ph.D.

Independent Director

--

Mr. John W. Childs

Independent Director

--

Mr. Kishen (Kishan) Mehta

Director

--

Dr. Vlad Coric, M.D.

Chairman of the Board, Chief Executive Officer

--

Name

Name/Position

Position

Shareholding

Change

Dr. Gregory Hugh (Greg) Bailey, M.D.

Independent Director

1.62M

--

Mr. Matthew (Matt) Buten

Chief Financial Officer

193.45K

+0.39%

Dr. Bruce Car, Ph.D.

Chief Scientific Officer

34.80K

+757.19%

Ms. Julia Paige Gregory

Independent Director

25.66K

--

Mr. Michael Thomas (Mike) Heffernan

Lead Independent Director

15.18K

--

Mr. Robert J. Hugin

Independent Director

12.96K

--

Revenue Breakdown

No Data

No Data

By Business

By Region

No Data

Shareholding Stats

Updated: Wed, May 14

Shareholders

Shareholder Types

Shareholders

Proportion

The Vanguard Group, Inc.

8.23%

1919 Investment Counsel, LLC

6.46%

Childs John W

6.38%

Janus Henderson Investors

6.30%

BlackRock Institutional Trust Company, N.A.

6.19%

Other

66.44%

Shareholders

Proportion

The Vanguard Group, Inc.

8.23%

1919 Investment Counsel, LLC

6.46%

Childs John W

6.38%

Janus Henderson Investors

6.30%

BlackRock Institutional Trust Company, N.A.

6.19%

Other

66.44%

Shareholder Types

Shareholders

Proportion

Investment Advisor/Hedge Fund

37.06%

Investment Advisor

28.02%

Hedge Fund

18.28%

Individual Investor

11.53%

Private Equity

2.88%

Research Firm

2.07%

Sovereign Wealth Fund

0.88%

Bank and Trust

0.64%

Venture Capital

0.51%

Institutional Shareholding

Updated: Tue, Jul 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q2

560

104.96M

102.79%

-7.46M

2025Q1

573

104.91M

102.74%

-8.33M

2024Q4

560

105.43M

103.87%

-2.30M

2024Q3

544

99.41M

101.90%

-4.10M

2024Q2

514

95.57M

103.25%

+3.60M

2024Q1

494

86.58M

104.39%

-3.45M

2023Q4

444

83.44M

104.38%

+4.72M

2023Q3

398

73.50M

107.61%

-2.29M

2023Q2

372

72.49M

106.13%

-7.40M

2023Q1

331

78.42M

114.97%

+3.79M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

8.40M

8.23%

+4.76K

+0.06%

Mar 31, 2025

1919 Investment Counsel, LLC

6.59M

6.46%

+34.44K

+0.53%

Mar 31, 2025

Childs John W

6.51M

6.38%

+351.58K

+5.71%

Mar 10, 2025

Janus Henderson Investors

6.44M

6.3%

-544.20K

-7.79%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

6.32M

6.19%

-61.68K

-0.97%

Mar 31, 2025

Suvretta Capital Management, LLC

5.62M

5.5%

--

Mar 31, 2025

Farallon Capital Management, L.L.C.

4.81M

4.71%

+385.00K

+8.69%

Mar 31, 2025

State Street Global Advisors (US)

3.42M

3.35%

-90.13K

-2.57%

Mar 31, 2025

Coric (Vladimir)

3.18M

3.11%

+26.57K

+0.84%

Mar 10, 2025

RP Management, LLC

2.94M

2.88%

--

Mar 31, 2025

Related ETFs

Updated: Sun, Jul 6

Name

Proportion

iShares Neuroscience and Healthcare ETF

2.32%

Roundhill GLP-1 & Weight Loss ETF

1.24%

Simplify Health Care ETF

1.16%

Global X Guru Index ETF

1.15%

Virtus LifeSci Biotech Clinical Trials ETF

0.85%

Tema Neuroscience and Mental Health ETF

0.56%

SPDR S&P Biotech ETF

0.45%

WisdomTree BioRevolution Fund

0.3%

Direxion Daily S&P Biotech Bull 3X Shares

0.26%

Main Thematic Innovation ETF

0.23%

iShares Neuroscience and Healthcare ETF

Proportion2.32%

Roundhill GLP-1 & Weight Loss ETF

Proportion1.24%

Simplify Health Care ETF

Proportion1.16%

Global X Guru Index ETF

Proportion1.15%

Virtus LifeSci Biotech Clinical Trials ETF

Proportion0.85%

Tema Neuroscience and Mental Health ETF

Proportion0.56%

SPDR S&P Biotech ETF

Proportion0.45%

WisdomTree BioRevolution Fund

Proportion0.3%

Direxion Daily S&P Biotech Bull 3X Shares

Proportion0.26%

Main Thematic Innovation ETF

Proportion0.23%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

15.110USD

Biohaven Ltd

15.110

Overview

Company

Financials